transmembrane protein 150CGenealiases: DRAM4 · TTN3
Q-omics provides the consensus-scored TMEM150C profile across patient tissues and cancer cell-line models. TMEM150C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM150C is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, TMEM150C RNA expression shows 19,573 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where TMEM150C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM150C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM150C survival associations across molecular data types. TMEM150C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM150C RNA expression–survival associations across cancer types. High TMEM150C expression shows unfavorable associations in BLCA, LGG and UVM, but favorable associations in KIRC, HNSC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM150C RNA expression.
This table summarizes TMEM150C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM150C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM150C shows lower tumor expression in KIRP, THCA, BLCA, KICH, HNSC and UCEC. The KIRP box plot shows higher TMEM150C RNA expression in normal versus tumor tissue (log2 FC = −2.100, t-test p < 0.001).
This table shows molecular features associated with TMEM150C in patient tissues and cancer cell lines. In patient samples, TMEM150C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM150C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
